Ani Pharms Company Profile
✉ Email this page to a colleague
What is the competitive landscape for ANI PHARMS, and what generic alternatives to ANI PHARMS drugs are available?
ANI PHARMS has two hundred and forty-two approved drugs.
There are four US patents protecting ANI PHARMS drugs. There is one tentative approval on ANI PHARMS drugs.
There are twenty-nine patent family members on ANI PHARMS drugs in twenty countries and one hundred and seventy supplementary protection certificates in sixteen countries.
Summary for Ani Pharms
| International Patents: | 29 |
| US Patents: | 4 |
| Tradenames: | 153 |
| Ingredients: | 146 |
| NDAs: | 242 |
Drugs and US Patents for Ani Pharms
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ani Pharms | BENAZEPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE | benazepril hydrochloride; hydrochlorothiazide | TABLET;ORAL | 076342-002 | Feb 11, 2004 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ||||
| Ani Pharms | THIORIDAZINE HYDROCHLORIDE | thioridazine hydrochloride | TABLET;ORAL | 088270-001 | Apr 14, 1983 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | |||||
| Ani Pharms | NORTRIPTYLINE HYDROCHLORIDE | nortriptyline hydrochloride | CAPSULE;ORAL | 074054-003 | Dec 31, 1992 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | |||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Ani Pharms
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Ani Pharms | ATACAND | candesartan cilexetil | TABLET;ORAL | 020838-001 | Jun 4, 1998 | 5,534,534*PED | ⤷ Sign Up |
| Ani Pharms | ATACAND | candesartan cilexetil | TABLET;ORAL | 020838-001 | Jun 4, 1998 | 5,196,444*PED | ⤷ Sign Up |
| Ani Pharms | BRETHINE | terbutaline sulfate | TABLET;ORAL | 017849-002 | Approved Prior to Jan 1, 1982 | 3,937,838 | ⤷ Sign Up |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Paragraph IV (Patent) Challenges for ANI PHARMS drugs
| Drugname | Dosage | Strength | Tradename | Submissiondate |
|---|---|---|---|---|
| ➤ Subscribe | Tablets | 16 mg/12.5 mg and 32 mg/12.5 mg | ➤ Subscribe | 2008-06-25 |
| ➤ Subscribe | Tablets | 4 mg, 8 mg, 16 mg and 32 mg | ➤ Subscribe | 2006-12-22 |
| ➤ Subscribe | Tablets | 32 mg/25 mg | ➤ Subscribe | 2009-03-06 |
International Patents for Ani Pharms Drugs
Supplementary Protection Certificates for Ani Pharms Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 1109558 | SPC/GB08/058 | United Kingdom | ⤷ Sign Up | PRODUCT NAME: RANOLAZINE OR A SALT OR SOLVATE THEREOF; REGISTERED: UK EU/1/08/462/001 20080714; UK EU/1/08/462/002 20080714; UK EU/1/08/462/003 20080714; UK EU/1/08/462/004 20080714; UK EU/1/08/462/005 20080714; UK EU/1/08/462/006 20080714 |
| 0459136 | 98C0016 | Belgium | ⤷ Sign Up | PRODUCT NAME: CANDESARTAN CILEXETIL; NAT. REGISTRATION NO/DATE: 212 IS 236 F3 19980119; FIRST REGISTRATION: GB PL 15661/0001 19970429 |
| 1856135 | 2020/017 | Ireland | ⤷ Sign Up | PRODUCT NAME: FOSTAMATINIB OR A PHARMACEUTICALLY ACCEPTABLE SALT OF FOSTAMATINIB, OR A HYDRATE, SOLVATE OR N-OXIDE OF FOSTAMATINIB OR THE PHARMACEUTICALLY ACCEPTABLE SALT OF FOSTAMATINIB, ESPECIALLY FOSTAMATINIB DISODIUM, OPTIONALLY IN FORM OF A HYDRATE; REGISTRATION NO/DATE: EU/1/19/1405 20200113 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
